By Trendlyne AnalysisThis lending company surged 15% over the past week after MD Rajesh Sharma said Capri Global expects its gold loan portfolio to grow around 40% this year. The firm plans to add 400 branches by December to support this expansion. Sharma said higher gold prices allow customers to borrow more against the same collateral while keeping loan-to-value ratios within a comfortable range.
Gold loans have been a key part of Capri Global’s growth since the company entered the segment four years ago. The business now accounts for about 48% of assets under management (AUM). Its portfolio more than doubled in FY26 and grew 13% QoQ in Q1, even as gold prices corrected. The company is focusing on smaller-ticket loans, which have helped improve yields to 18.5%.
The bigger opportunity is improving branch productivity. Capri had about 1,000 gold loan branches in Q1, with AUM per branch at roughly Rs 19 crore. This compares with around Rs 32.5 crore for Muthoot Finance and Rs 14 crore for Manappuram Finance. Sharma said existing branches can deliver around 25% annual growth even without higher gold prices, while new branches should provide an additional boost.
Management expects gold loans to account for around 55% of AUM over the medium term, leaving room for its other lending businesses to grow alongside the main franchise. Housing AUM grew 42% YoY in Q1 while MSME and construction finance rose 24% and 40% respectively. During the latest earnings call, Sharma raised the annual AUM outlook by 6% and said, “We are on course to achieve Rs 50,000 crore by FY27 and Rs 65,000 crore by FY28”.
Deven Choksey reiterates its ‘Buy’ rating with a target price of Rs 316. The brokerage sees Capri Global at an inflection point as its gold loan business shifts from branch-led expansion to a more scalable, volume-driven model. However, it flags the relatively young gold loan book as a key monitorable and says the company still needs to prove that current returns can hold through a full gold-price cycle.
The stock of this power & electric utilities company fell 3.3% on August 27 after the Singapore International Commercial Court dismissed its challenge against a $490 million arbitration award owed to Kleros Capital Partners. Unwilling to back down, the power utility plans to file an appeal within the mandatory 28 day window.
The legal battle traces back to Tata Power's proposed participation in Russia's Krutogorovo coal project. Kleros dragged the company into arbitration in November 2020, alleging contract breaches and confidentiality violations. By September 2023, the tribunal held Tata Power liable for contractual breaches, ultimately ordering the firm on July 1, 2025, to pay $490.3 million in damages plus interest and legal costs.
Beyond courtroom battles, the company continues to charge ahead in the renewable energy space. On August 24, its arm Tata Power Renewable Energy commissioned 190.5 MW of a solar project in Kalasar, Bikaner, Rajasthan, pushing total renewable utility capacity to 12.4 GW. Adding to this green push, the company installed over 61,000 rooftop solar units across Kerala, representing a cumulative installed capacity exceeding 273 MW across the state.
Looking ahead, Tata Power aims to more than sixfold rooftop solar revenue to Rs 30,000 crore by 2029 and double its market share to nearly 25%. MD & CEO Praveer Sinha expects to achieve the revenue target ahead of the earlier 2030 guidance, noting that rooftop solar revenue nearly doubled to Rs 4,800 crore last year.
Trendlyne’s Forecaster projects Tata Power Q2FY27 net income to rise 20.8% on the back of robust domestic power demand. Analysts point out that Tata Power controls premier power distribution licenses across Delhi and Mumbai, while newly acquired Odisha discoms are already showing operational gains post takeover. The stock features in a screener of companies whose book value per share has improved over the past two years.
This biotech company rose 1.9% on Tuesday after its subsidiary Biocon Biologics won approval for its pegfilgrastim biosimilar in Japan. Pegfilgrastim prevents chemotherapy-induced loss of white blood cells, lowering the risk of serious infections and fever. Biocon will manufacture the drug, while Sandoz will exclusively promote, sell and distribute it in Japan.
Biosimilars are cheaper versions of biologics, which are drugs made using living cells. They are designed to work as effectively as the original drug. The company already sells a pegfilgrastim biosimilar under the Fulphila brand in the US. Fulphila still holds about 20-25% of the US market after its launch in 2018.
Biosimilars generated 66% of Biocon’s Q1FY27 revenue, and sales grew 16% YoY. Management expects growth to pick up in H2 as recent launches contribute more. Yesafili, which treats eye conditions linked to ageing and diabetes, entered the US market after Q1. Wider insurance coverage and distribution could support sales from two other US launches for osteoporosis and cancer-related bone complications.
Biocon is also expanding insulin supplies after European regulators approved a second filling and packaging line at its Malaysia plant. The new line doubles capacity, with supplies expected to pick up in Q2. The generics business reported EBITDA of Rs 56 crore in Q1, against an operating loss a year earlier. Cost cuts and a better product mix drove the turnaround.
The services business is the main drag. Syngene’s revenue fell 16% in Q1 due to reduced demand from a key biologics client. Its EBITDA margin fell ten percentage points to 15%. Executive Chairperson Kiran Mazumdar-Shaw said, “Performance should improve in H2, limiting the FY27 revenue decline to a single digit, with EBITDA margins returning to the mid-20s.”
Motilal Oswal reiterated its ‘Buy’ rating and raised its target price to Rs 520. The brokerage expects revenue in both biosimilars and generics to grow about 16% annually through FY28.
The stock of this hotels company climbed over 5% in the past week following management's ambitious plans to expand its luxury portfolio. Central to this growth is its premium brand, Athiva, launched last October to target affluent Indians and millennials. Managing Director Shwetank Singh highlighted the addition of two new Athiva properties in Pune and Hyderabad, which will bring 381 keys to these commercial hubs over the next 3 to 5 years. With these projects underway, the total inventory for the company, including its active pipeline, will expand to 5,500 keys.
Even as Chalet pushed forward with expansion, its Q1 performance took a hit from geopolitical tensions in West Asia. Global travel disruptions led to a sharp slowdown in foreign tourist arrivals as international travelers delayed or cancelled trips due to safety concerns. Driven primarily by weakness in its real estate segment, Q1FY27 revenue dropped 42.6% YoY to Rs 2,582 crore. However, its operating revenue surpassed Trendlyne’s Forecaster estimates by 2.6% as management noted a domestic demand recovery in June. The stock features in a screener of companies that have outperformed their industry over the past month.
Management maintained its guidance for stable demand and a recovery in H2FY27. Expansion plans remain on track, with Westin Powai renovations and the Vashi hotel rebranding expected to be completed in FY27. The Taj Delhi airport hotel’s planned 380-key addition and Cignus Powai Tower II are expected to commence operations in Q4FY27, while Athiva Goa is slated to open in FY28.
Nomura maintained a ‘Neutral’ rating on Chalet Hotels, anticipating that improving hotel EBITDA margins will support a 2% upward revision in FY27 and FY28 EBITDA estimates. However, the brokerage cautioned investors to closely monitor occupancy ramp-ups, noting that 30% of the company's portfolio is currently affected by renovation and construction, making timely project delivery essential for sustained growth.
This iron & steel products manufacturer soared last week, hitting an all-time high of Rs 2,443.9. The surge followed a Rs 17,200 crore order to supply pipes from its US plant, pushing the total order book to about Rs 42,100 crore.
ICICI Direct analysts noted that this contract provides multi-year revenue visibility and reduces the company's reliance on short-cycle orders. The deal will keep the US manufacturing facility running near full capacity, boosting regional profitability and operational leverage over the next two years.
The recent surge builds on the stock's momentum after strong Q1FY27 results and FY27 outlook. Net profit surged three-fold, nearly 2.8x the Forecaster estimate. Cheaper raw materials and a one-time gain from a partial stake sale of its Saudi subsidiary, East Pipes Integrated Co, drove this earnings jump.
Post results, MD and CEO Vipul Mathur commented on the outlook, saying, “We maintain our FY27 revenue growth guidance of 18%, with EBITDA rising 20%.”
Management expects the growth to be fueled by demand across geographies. LNG exports to the US, recovery in onshore & offshore oil pipelines, and rising power demand from AI data centres will boost US exports. Oil & gas investments by Aramco, desalinated water transportation projects and reconstruction opportunities due to the conflict will drive the West Asia business. Lastly, demand from energy, defence and other key sectors will support the Indian business.
As these positive developments pushed the stock up 50.7% over the past month, insiders cashed in on the rally. Promoters Welspun Investments & Commercials and MD Vipul Mathur sold a 2.3% stake worth Rs 1,417 crore through a block deal.
Following the mega order, Nuvama retained a ‘Buy’ rating and raised its target price to Rs 2,656. The brokerage expects strong project execution, expansion in West Asia, and upcoming capacity additions to drive long-term earnings growth. Analysts also expect the domestic line-pipe business to rebound sharply as new LNG terminals expand India's city gas distribution networks.
Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.